

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7252644

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
MEDIZINISCHE UNIVERSITAT WIEN	12/03/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	WILSON THERAPEUTICS AB
<b>Street Address:</b>	KUNGSGATAN 3
<b>City:</b>	STOCKHOLM
<b>State/Country:</b>	SWEDEN
<b>Postal Code:</b>	111 43
<b>PROPERTY NUMBERS Total: 3</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	16770022
<b>Application Number:</b>	16997928
<b>Application Number:</b>	17182227
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	patents@alexion.com
<b>Correspondent Name:</b>	ALEXION PHARMACEUTICALS, INC.
<b>Address Line 1:</b>	100 COLLEGE STREET
<b>Address Line 4:</b>	NEW HAVEN, CONNECTICUT 06510
<b>ATTORNEY DOCKET NUMBER:</b>	0541 US MEDIZIN-WILSON AB
<b>NAME OF SUBMITTER:</b>	DARLENE SUAREZ
<b>SIGNATURE:</b>	/DARLENE SUAREZ/
<b>DATE SIGNED:</b>	03/30/2022
<b>Total Attachments: 5</b>	
source=5. Signed Assignment between Medizinische Universitat Wien & Wilson Therapeutics AB0541#page1.tif	
source=5. Signed Assignment between Medizinische Universitat Wien & Wilson Therapeutics AB0541#page2.tif	
source=5. Signed Assignment between Medizinische Universitat Wien & Wilson Therapeutics AB0541#page3.tif	
source=5. Signed Assignment between Medizinische Universitat Wien & Wilson Therapeutics AB0541#page4.tif	
source=5. Signed Assignment between Medizinische Universitat Wien & Wilson Therapeutics AB0541#page5.tif	

PATENT

ASSIGNMENT OF PATENT RIGHTS

**Medizinische Universität Wien**, Spitalgasse 23, 1090 Wien, Austria (herein referred to as "Assignor") owns the entire right, title and interest in any Letters Patent(s) ("said patent(s)") and any Patent application(s) ("said application(s)") set forth below, as well as any invention(s) ("said invention(s)") disclosed in said application(s) and said patent(s).

Patent Application(s)

Application Serial No.: <b>62/594,184</b>	File Date: <b>December 4, 2017</b>
Application Serial No.: <b>62/646,553</b>	File Date: <b>March 22, 2018</b>
Application Serial No.: <b>62/655,568</b>	File Date: <b>April 10, 2018</b>
Application Serial No.: <b>62/669,095</b>	File Date: <b>May 9, 2018</b>
Application Serial No.: <b>62/741,313</b>	File Date: <b>October 4, 2018</b>
Application Serial No.: <b>62/750,595</b>	File Date: <b>October 25, 2018</b>
Application Serial No.:	File Date:
Application Serial No.:	File Date:

Title: **METHODS OF TREATING WILSON DISEASE**

WHEREAS, **Wilson Therapeutics AB**, a corporation having its principal place of business at Kungsgatan 3, Stockholm, Sweden, SE-111 43, its successors, legal representatives and assigns (the "Assignee"), is desirous of acquiring the entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any applications for Letters Patent of the United States or other countries claiming priority to said application(s), the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) and said patent(s), and the entire right, title, and interest in and to any and all Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s);

NOW, THEREFORE, for good and sufficient consideration, the receipt of which is hereby acknowledged, the Assignor does hereby sell, assign, transfer, and set over, unto the Assignee, its successors, legal representatives, and assigns the entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), the right to file applications on said invention(s), the entire right, title and interest in and to any

applications for Letters Patent of the United States or other countries claiming priority to said application(s), including divisions, continuations, and continuations-in-part of said application(s), the right to recover any and all past, present, and future damages, including provisional or other royalties, for any and all past, present, and future infringements of said application(s) and said patent(s), the entire right, title and interest in and to any and all Letters Patent or Patents, United States or foreign, to be obtained for said invention(s) and said application(s), the entire right, title and interest in and to any and all reissues and extensions of said patent(s), and all rights under the Hague Convention, the Paris Convention for the Protection of Industrial Property, and under the Patent Cooperation Treaty, the same to be held and enjoyed by the Assignee, for its own use and behalf and the use and behalf of its successors, legal representatives, and assigns, to the full end of the term or terms for which Letters Patent or Patents may be granted as fully and entirely as the same would have been held and enjoyed by the Assignor had this sale and assignment not been made;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns, that, at the time of execution and delivery of these presents, the Assignor is the sole and lawful owner of the entire right, title, and interest in and to said invention(s), said application(s), and said patent(s), and that the same are unencumbered, and that the Assignor has good and full right and lawful authority to sell and convey the same in the manner herein set forth;

AND for the same consideration, the Assignor hereby covenants and agrees to and with the Assignee, its successors, legal representatives, and assigns that the Assignor will, whenever counsel of the Assignee, or the counsel of its successors, legal representatives, and assigns, shall advise that any proceeding in connection with said invention(s), said application(s), said patent(s), any application claiming priority to said application(s), any reissue or extension of said patent(s), and any United States or foreign Letters Patent or Patents for said invention(s) or said application(s), including interference and derivation proceedings, and any post-grant proceedings (e.g., opposition proceedings, post-grant reviews, *Inter partes* reviews, supplemental examinations, etc.), is lawful and desirable, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the procurement, maintenance, enforcement and defense of Letters Patent or Patents for said invention(s) at the cost and expense of the Assignee, its successors, legal representatives, and assigns;

AND the Assignor hereby authorizes and requests the attorneys of COOLEY LLP to insert in the spaces provided above the filing date, the application number, and the attorney docket number of the application(s) identified above when known;

AND the Assignor hereby requests the Commissioner of Patents to issue any and all aforementioned patent(s) of the United States to the Assignee, as the Assignee of said invention(s) and the Letters Patent to be issued thereon for the sole use and behalf of the Assignee, its successors, legal representatives, and assigns.

**Attorney Docket Nos. WLSN-006 Family**

Page 3 of 5


179824795 v1

**PATENT**  
**REEL: 059439 FRAME: 0789**

Date: 3<sup>rd</sup> Dec 2018

By:   
Medizinische Universität Wien

Witness Date: 3<sup>rd</sup> Dec 2018


Witnessed By:   
Helga Kroschewski

For and on behalf of ASSIGNEE:

Date: 12-04-2018

By:   
Wilson Therapeutics AB

Witness Date: 12/4/18

Witnessed By:   
LAUREL BOONE